Thermo Fisher Scientific, TG Therapeutics, AbbVie, Vertex Pharmaceuticals, and BioCryst Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use living organisms or biological processes to develop products such as drugs, diagnostics and medical devices. Because these firms typically incur high research-and-development costs and depend on clinical trials and regulatory approvals, their share prices can be highly volatile. Investors in biotech stocks are often attracted by the potential for major medical breakthroughs—and significant returns—but must also be prepared for long development timelines and binary (success-or-failure) outcomes. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of TMO traded down $2.72 during trading hours on Monday, reaching $420.83. The stock had a trading volume of 854,665 shares, compared to its average volume of 1,765,871. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a 50-day simple moving average of $476.15 and a 200 day simple moving average of $520.61. The company has a market capitalization of $158.86 billion, a price-to-earnings ratio of 25.47, a P/E/G ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific has a 12 month low of $409.85 and a 12 month high of $627.88.
Read Our Latest Research Report on TMO
TG Therapeutics (TGTX)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Shares of TG Therapeutics stock traded down $5.83 on Monday, hitting $37.61. The company had a trading volume of 7,244,030 shares, compared to its average volume of 3,001,469. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a 50 day moving average of $38.56 and a 200-day moving average of $33.31. TG Therapeutics has a 1 year low of $15.16 and a 1 year high of $46.48. The stock has a market capitalization of $5.97 billion, a price-to-earnings ratio of -377.01 and a beta of 2.21.
Read Our Latest Research Report on TGTX
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded down $2.38 during midday trading on Monday, hitting $196.09. 1,080,205 shares of the stock were exchanged, compared to its average volume of 6,062,276. AbbVie has a 52-week low of $153.58 and a 52-week high of $218.66. The business's 50-day moving average price is $196.14 and its 200-day moving average price is $187.22. The stock has a market capitalization of $346.89 billion, a price-to-earnings ratio of 81.64, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94.
Read Our Latest Research Report on ABBV
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ VRTX traded up $3.09 during mid-day trading on Monday, reaching $504.24. 395,619 shares of the company's stock were exchanged, compared to its average volume of 1,340,108. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a 50-day moving average price of $492.00 and a two-hundred day moving average price of $466.79. The firm has a market capitalization of $129.63 billion, a price-to-earnings ratio of -229.17, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.
Read Our Latest Research Report on VRTX
BioCryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
BioCryst Pharmaceuticals stock traded up $1.32 during midday trading on Monday, reaching $10.25. The stock had a trading volume of 12,098,175 shares, compared to its average volume of 2,867,948. The firm has a market capitalization of $2.14 billion, a PE ratio of -16.94 and a beta of 1.08. The firm's 50-day moving average price is $7.69 and its 200 day moving average price is $7.80. BioCryst Pharmaceuticals has a 12 month low of $4.75 and a 12 month high of $11.48.
Read Our Latest Research Report on BCRX
Recommended Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
